

- Press Release -

KAREN PINACHYAN JOINS LFB AS EXECUTIVE VICE PRESIDENT, SCIENTIFIC, MEDICAL & REGULATORY AFFAIRS

Les Ulis (France) – 18 November 2024 – LFB is pleased to announce the appointment of Karen Pinachyan to its Executive Committee as Executive Vice President, Scientific, Medical & Regulatory Affairs and Chief Medical Officer. Karen Pinachyan succeeds Patrick Delavault, who is retiring after a career dedicated to advancing medical innovation and will now devote himself fully to academic activities. In this new role, Karen Pinachyan will report directly to Jacques Brom, CEO of LFB.

Before joining LFB, Karen Pinachyan was the Head of Global Medical Affairs for the Hematology Therapeutic Area at CSL Behring. Prior to this, Karen served as the Head of Medical Affairs for the European region at CSL Behring, where he oversaw medical strategies across key therapeutic areas, including immunology, cardiology, and transplantation.

Karen Pinachyan completed his specialization in otorhinolaryngology and head and neck surgery at the University Hospital of Marseille in France, where he also developed expertise in toxicology and pharmacovigilance. He holds a specialized Master's degree in Healthcare Management and a diploma in Public Health.

He then transitioned to the biotechnology sector, successfully leading orphan drug designation applications with both the EMA and the FDA for cutting-edge molecules within a Marseille-based startup. Before joining CSL Behring in 2019, he also held roles in medical affairs and clinical development at Boehringer Ingelheim, Octapharma, and Roche, demonstrating a rich and varied experience across several European settings.

Karen Pinachyan will bring his vision and expertise to support patients with serious and rare diseases, a mission that lies at the heart of LFB's priorities. By joining the group, he will contribute to enhancing the impact of LFB's medicines and supporting its global ambitions.

According to Jacques Brom, CEO of LFB: *"We are delighted to welcome Karen Pinachyan to our team. His expertise, particularly in the development of plasma-derived medicines, will be a valuable asset in supporting our innovation strategy and meeting patient needs. We extend our heartfelt thanks to Patrick Delavault for his commitment to LFB over the past six years."*

About LFB

LFB is a biopharmaceutical group that develops, manufactures and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients with serious and often rare diseases. Created in France in 1994, LFB today is a leading European company providing plasma-derived medicinal products to healthcare professionals. Its mission is to offer patients new treatment options for unmet needs in three major therapeutic areas: immunology, haemostasis and intensive care. LFB's current market portfolio includes 15 biomedicinal products sold in about 30 countries. For more information on LFB, go to www.groupe-lfb.com.

LFB contact person:

Didier Véron – Executive Vice President, Corporate Affairs

Phone: +33 (0)1.69.82.72.97 or +33 (0)6.08.56.76.54 –

Email: verondidier@lfb.fr